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Experience of temporary inferior vena cava filters
inserted in the perinatal period to prevent
pulmonary embolism in pregnant women with
deep vein thrombosis
Kazuya Kawamata, MD,a Yoshihide Chiba, MD,a Ryoichi Tanaka, MD,b Masahiro Higashi, MD,b and
Kazuhiro Nishigami, MD,c Osaka, Japan
Objective: We placed temporary inferior vena cava filters to prevent pulmonary thromboembolism in patients with deep
vein thrombosis (DVT) who were presumed to have an increased risk of pulmonary embolism in the perinatal period.
These experiences of using temporary inferior vena cava filters in pregnant women are reported.
Methods: We reviewed 11 patients with DVT who underwent placement of a temporary inferior vena cava filter and
delivered in our hospital between 1998 and 2004. All of the filters were placed at the suprarenal inferior vena cava before
delivery. During filter placement, anticoagulant therapy was routinely performed, and we stopped the administration of
anticoagulant agents intrapartum.
Results: No complications occurred at filter insertion or during placement. No symptomatic pulmonary thromboembo-
lism occurred during or after delivery. All of the filters were successfully removed, one of which was exchanged for a
permanent filter because the temporary filter captured a large thrombus.
Conclusion: Intrapartum temporary inferior vena cava filters may reduce the incidence of pulmonary thromboembolism
in pregnancy with DVT. Temporary inferior vena cava filters appear to be safe for pregnant women. (J Vasc Surg 2005;
41:652-6.)Pulmonary thromboembolism is a major cause of ma-
ternal mortality and the third highest cause of maternal
death in Japan.1 Pulmonary emboli may develop from deep
vein thrombosis (DVT),2 particularly during labor or just
after delivery. We describe the implantation of a temporary
inferior vena cava filter (t-IVCF) in patients with DVT to
prevent pulmonary thromboemboli from forming during
the perinatal period, and report our experience with t-IVCF
placement and associated complications in a cohort of
pregnant women peripartum.
MATERIALS AND METHODS
Between 1998 and 2004, we examined 17 patients (21
pregnancies) with DVT that occurred during pregnancy, or
that had already developed before their pregnancy, and
evaluated their histories. DVT was evaluated with duplex
scanning just before delivery to determine if the insertion of
a t-IVCF was indicated. Eleven patients, all of whom had
thrombophilia, were selected among the 21 patients with
DVT. The indication for t-IVCF insertion was the identi-
fication of one or more of the following three factors:
1. DVT developed during the current pregnancy;
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6522. a history of DVT or pulmonary thromboemboli treated
with anticoagulant agents when not pregnant;
3. floating thrombi present in the veins of the lower limbs
or inferior vena cava.
All patients in categories 1 and 2 were administered
dose-adjusted heparin as a therapeutic dose during preg-
nancy. We inserted 12 t-IVCFs into 11 patients (one pa-
tient received 2 filters) who were presumed to have an
increased risk of pulmonary embolism in the perinatal
period. The maternal backgrounds and the outcomes are
summarized in Tables I and II.
All coagulation parameters, including protein C, pro-
tein S, antithrombin III, lupus anticoagulant antibodies,
and anticardiolipin antibodies were examined. Before
transvaginal or cesarean delivery, we used videofluoro-
scopic guidance to inserted t- IVCFs. The fetus was
shielded as much as possible with a lead shield. The filters
were percutaneously inserted under local anesthesia
through the right internal jugular vein or right upper
extremity for a first-time insertion. The filters were deliv-
ered through an 8F long introducer sheath and secured to
the skin. The t-IVCFs were placed in the suprarenal inferior
vena cava.
We used Neuhaus Protect (Toray Medical, Tokyo,
Japan) or Antheor (Boston Scientific, Watertown, Mass) as
the temporary filter. Anticoagulant therapy was adminis-
tered in all patients during filter placement by means of
intravenous heparin dose-adjusted to maintain an activated
partial thromboplastin time at 1.5 to 2 times that of the
control value. Heparin anticoagulant therapy was stopped
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Patient Age BMI G/P Laterality DVT onset DVT Cause DVT Location
Anticoagulation
during pregnancy
Thrombophilic or
other complications
1 27 21 G1PO R 12 week Catheter EIV Heparin (therapeutic) Post-operation of
PDA
2 32 22 G3P3 L Prev preg Pregnancy EIV Heparin (therapeutic) LAC positive
3 30 22 G0P0 L 27 weeks Pregnancy CIV Heparin (therapeutic) No
4 32 19 G1P1 L 7 weeks Pregnancy CIV Heparin (therapeutic) Protein S deficiency
5 33 22 G2P2 L 36 weeks Pregnancy CIV Heparin (therapeutic) No
6 24 18 G1P1 R Unknown Catheter EIV no Post-operation of
VSD
7 39 20 G0T0 R 18 weeks Pregnancy FV Heparin (therapeutic) Protein S deficiency
8 27 18 G1P0 — 13 weeks Pregnancy IVC Heparin (therapeutic) No
9 28 17 G2P1 — Prev preg Pregnancy IVC no No
10 33 21 G0P0 L 25 weeks Pregnancy CIV Heparin (therapeutic) Protein S deficiency
11 34 23 G2P2 L Before
preg
LAC
positive
EIV Heparin (therapeutic) LAC positiveBMI, Body mass index; G, gravida; P, para; DVT, deep vein thrombosis; EIV, external iliac vein; CIV, common iliac vein; IVC, inferior vena cava; FV, femoral
vein; PDA, persistent ductus arteriosus; LAC, lupus anticoagulant; VSD, ventricular septal defectTable II. Outcome
Patient
Gestational
age at
delivery
Category of
indication†
Route of
filter
placement
Filter
type
Duration
(days) Thrombus
Mode of
delivery Emergency
Anticoagulation
postpartum
1 36 *1 IJV Antheor 9 Mixed CS No Heparin
(therapeutic),
warfarin
2 37 ‡2 UV Antheor 11 Fresh VD No Heparin
(therapeutic),
warfarin
3 38 *1 CV Antheor 7 Fresh VD No Heparin
(therapeutic),
warfarin
4 33 *1 CV FV IJV Antheor 14 Fresh CS Yes Heparin
(therapeutic),
warfarin
5 40 *1 CV Antheor 3 No VD No Heparin
(therapeutic),
warfarin
6 38 §3 CV Antheor 4 No VD No Heparin
(prophylactic)
7 39 *1 CV Antheor 6 Fresh VD No Heparin
(therapeutic),
warfarin
8 37 *1 CV Antheor 8 Fresh VD No Heparin
(therapeutic),
warfarin
9 37 §3 IJV Neuhaus
protect
4 Fresh VD No Heparin
(prophylactic)
10 37 *1 IJV Antheor 7 Fresh VD Yes Heparin
(therapeutic),
warfarin
11 37 ‡2 IJV Antheor 5 Fresh VD Yes Heparin
(therapeutic),
warfarin
IJV, Internal jugular vein; FV,femoral vein; CV, cubital vein; CS, cesarean section; VD, vaginal delivery.
† *1. Patients developed deep vein thrombosis during pregnancy.
‡2. Patients who had a history of deep vein thrombosis or pulmonary thromboemboli and were treated with anticoagulant agents when they were not pregnant.
§3. Patients who had floating thrombi in the veins of their lower limbs or inferior vena cava.
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Anticoagulation was restarted 6 hours after a vaginal deliv-
ery and 12 hours after a cesarean section delivery.
We checked for the presence of thrombi in the filter by
using computed tomography (CT) or duplex Doppler
scanning 3 to 5 days after delivery, and the area around the
filter was again examined by angiography before it was
removed. The filter was removed if there was no adhesion
of large thrombi detected that could develop into a pulmo-
nary embolism. When a thrombus was present in the filter,
we performed thrombolysis by the systemic administration
of urokinase.
All patients were followed-up at an outpatient clinic for
6 months after delivery. In addition to these investiga-
tions, patients were also examined for complications result-
ing from the filter implantation.
RESULTS
The mean age SD of the 11 patients in this study was
30.8 4.2years. DVT was present in the inferior vena cava
in 2 patients, the iliac vein in 8, and the femoral vein in 1
patient. The thrombi were present on the left side in six
patients and on the right in three patients, except for
thrombi present in the inferior vena cava. DVT developed
before pregnancy or during pregnancy in all patients, ex-
cept for one. Three patients had protein S deficiency, and
two had lupus anticoagulant. Two patients had a history of
cardiac surgery.
Multiple examinations with cardiac catheter that is
inserted in the right femoral vein can lead to obstruction or
stenosis of the femoral vein and result in increased stasis.
Pregnancy complicated by hypercoagulability may lead to
the development of DVT. We administered intravenous or
subcutaneous heparin during pregnancy to all but two
patients.
The t-IVCFs were easily placed, and the duration of
fluoroscopy used during placement was usually 2 min-
utes. The mean duration of the placement of a filter was 7.1
 3.3 days, and complications such as pulmonary throm-
boembolism, hemorrhage, or infection were not observed.
In addition, no perioperative fetal or maternal morbidity or
mortality noted.
We identified small thrombi in the catheters after re-
moval in eight patients, and almost all were freshly formed
as seen by their pathologic findings (Fig 1). A large throm-
bus was captured in the filter for patient 4, which was
considered to have arisen from DVT in a lower extremity.
We performed thrombolytic therapy by the systemic ad-
ministration of 48,0000 IU/day urokinase for 1 week, but
the thrombus could not be dissolved. We therefore placed
another t-IVCF using a femoral approach, having had
removed the first inserted filter via the cubital vein a week
earlier (Fig 2). Thrombolytic therapy (48,0000 IU/day
urokinase) was sequentially started for 1 week, but despite
the combined 2-week treatment, the thrombus did not
completely dissolve. We finally placed a permanent filter in
this patient. Postpartum bleeding during the systemic ad-
ministration of urokinase did not increase.Insertion of the t-IVCF occurred without trouble even
when done as an emergency procedure in three patients,
including during labor or after the decision to perform a
cesarean section was made. During the follow-up period,
no pulmonary emboli or other filter-related complications
were observed.
DISCUSSION
The mortality rate for patients with pulmonary throm-
boemboli that form during the perinatal period is high, and
the management of pregnant woman with thrombophilia
and DVT is difficult. Anticoagulant therapy is necessary for
these patients even when they are not pregnant, and it
should be continued during pregnancy.3-5 We always ad-
minister full-dose heparin throughout pregnancy for pa-
tients who have thrombophilia and for those who develop
DVT during this period. However, it must be discontinued
to avoid hemorrhaging during vaginal or cesarean delivery
and the occurrence of an epidural hematoma.6,7 The with-
drawal of anticoagulants can lead to pulmonary embolism,
for which we have placed t-IVCFs into patients with DVT
during the last 7 years.
Recently, several reports on the prevention of perinatal
pulmonary thromboemboli from forming by using a
Greenfield filter have been published,8-10 but this filter is
permanent. The placement of a permanent filter in young
woman should be undertaken with caution. Temporary
inferior vena cava filters can take the place of permanent
IVCF for preventing the formation of pulmonary throm-
boemboli for a short period, as seen in our study. In
addition, no complications were observed for the place-
ment of the t-IVCFs.
Definitive indications for the placement of a t-IVCF
have not been established. Linsenmaier et al11 advocated
the indication for a t-IVCF under the following circum-
stances: the existence of DVT and temporary contraindica-
tions for anticoagulation, pulmonary embolism despite
DVT prophylaxis, and a high risk for forming pulmonary
emboli for cases of severe trauma and high perioperative
risk.
The patients that we selected for this study were pre-
sumed to have an increased risk of pulmonary embolism in
the perinatal period, and those who received anticoagulant
therapy during pregnancy had to stop it at this time. No
evidence suggests that the risk of intrapartum pulmonary
embolism increased upon withdraw from heparin adminis-
tration for patients with DVT. Kearon et al12 described the
risk for new thrombi that developed within 2 weeks for a
nonpregnant population.
Although pregnant women are always in a hypercoag-
ulable state, we believe that it is important to take preven-
tative measures whether the thrombus is new or old. Other
indications for a t-IVCF include the presence of a floating
thrombus documented by duplex or CT scanning that may
result in the development of a pulmonary thromboem-
boli.13 Among our cohort, we did not perform anticoagu-
lant therapy in the antepartum period for patients 6 and 9
because these thrombi were thought to have been old,
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ter.Fig 2. Helical computed tomography that was digitally reconstructed shows a captured large thrombus (arrow) that
arose from the lower extremity in patient 4. The Antheor system was implanted into the supra renal inferior vena cava,
and we performed thrombolytic therapy to dissolve the thrombus, but it did not dissolve despite the treatment. This
image was taken after the filter was replaced. The appearing filter is the second filter inserted from femoral vein.
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tion just before delivery. We also believe that further inves-
tigation of the indication for using a t-IVCF on pregnant
women with DVT should be performed.
The t-IVCFs used in this study were placed in the
suprarenal inferior vena cava along with the sheath and its
catheter. The detached type of filter is beneficial from the
aspect of infection, but we found that even the catheter-
attached type device that we used could be placed without
any problems for a short period of time. It is comparatively
easier to place a t-IVCF than it is a permanent filter.
Furthermore, the injection of contrast medium during
removal is also easy because the attached catheter has
another port, and we did not have to puncture the patients
again for fluoroscopy when searching for thrombi around
the filter during removal.
When we examined the filters after removal, fresh
thrombi were often found to have adhered, and it seemed
that they had formed because of the placement itself.
However, these thrombi were too small to cause changes in
the circulatory dynamics of the patients or to cause the
development of severe pulmonary thromboemboli.
One large thrombus arising from DVT was captured in
a filter; therefore, the t-IVCF was effective at preventing a
pulmonary embolism from forming during delivery in this
patient. Some patients will develop pulmonary emboli de-
spite adequate anticoagulant therapy,14,15 and pulmonary
emboli may develop in patients with DVT when anticoag-
ulant therapy is temporarily withdrawn during the perinatal
period.
Venous injury or perforation, the recurrence of DVT,
thrombi present in the inferior vena cava or at the site of
filter insertion, postphlebitic syndrome, and misplacement
of the filter are possible complications associated with the
permanent form of the inferior vena cava filter. The inferior
vena cava contacts with the gravid uterus, and because this
is enlarged, filter migrationmight occur. The filter has to be
placed cranial to the orifice of the renal veins because a
dilated ovarian vein may be a possible source of thrombi in
patients with a DVT complicating childbirth.16 Brenner et
al17 described the risks associated with a suprarenal perma-
nent filter with regard to renal dysfunction. The insertion of
a permanent inferior vena cava filter into a pregnant woman
should therefore be performed only in limited circum-
stances.
The handling of a t-IVCF is simple, and it is as effective
as a permanent inferior vena cava filter at preventing pul-
monary thromboembolism over a short period. The use ofa temporary filter to prevent pulmonary thromboemboli
from forming during the perinatal period for pregnant
women with DVT is safe, and thus its prophylactic use for
pregnant women with DVT may be justified.
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